Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: GlobeNewswire
Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3 trial in MDD for AXS-05 still anticipated in 2H 2019 Phase 3 MOMENTUM trial of AXS-07 in migraine on track for readout of topline results in 2H 2019 Phase 2 CONCERT trial results of AXS-12 in narcolepsy now anticipated in 2H 2019 Current cash sufficient to fund anticipated operations beyond all clinical trial readouts NEW YORK, June 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is providing the following update on the Company’s continued progress at its Annual Meeting of Stockholders being held today: AXS-05 AXS-05 (dextromethorphan/bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed f
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $150.00 price target on the stock.MarketBeat
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at HC Wainwright from $180.00 to $190.00. They now have a "buy" rating on the stock.MarketBeat
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Citigroup Inc. from $125.00 to $127.00. They now have a "buy" rating on the stock.MarketBeat
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Royal Bank of Canada from $123.00 to $128.00. They now have an "outperform" rating on the stock.MarketBeat
AXSM
Earnings
- 2/20/24 - Miss
AXSM
Sec Filings
- 3/25/24 - Form 8-K
- 3/25/24 - Form 8-K
- 3/19/24 - Form 8-K
- AXSM's page on the SEC website